Central Insulin Sensitivity in Individuals With Type 2 Diabetes (T2D) and at Risk for Developing T2D

NARecruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Central Insulin ResistanceDiabetes Mellitus, Type 2PreDiabetes

Interventions

OTHER

Human nasal insulin

single dose of 160 U of human insulin as nasal spray

OTHER

Placebo

Single dose of placebo solution as nasal spray

Trial Locations (1)

RECRUITING

University Hospital Tübingen, Tübingen

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER